Tenatumomab I 131

Drug Profile

Tenatumomab I 131

Alternative Names: 131I-Tenatumomab; 131Iodine-Tenatumomab; I131 anti-Tenascin monoclonal antibody; Tenatumomab/ST2146

Latest Information Update: 16 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sigma-tau SpA
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Immunomodulators; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 04 Nov 2016 sigma-tau SpA suspends enrolment in a phase I trial in Cancer (In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in France and Italy (NCT02602067)
  • 01 Nov 2015 Phase-I clinical trials in Cancer (Second-line therapy or greater, In adults, In the elderly, Late-stage disease) in France and Italy (IV) (NCT02602067)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top